Silverarc Capital Management, LLC Immuno Gen, Inc. Transaction History

Silverarc Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$14.09 - $19.87 $1.59 Million - $2.24 Million	-112,565 Reduced 7.93%	1,307,435 $20.7 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $4.76 Million - $25.5 Million	1,270,000 Added 846.67%	1,420,000 $26.8 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $944,177 - $1.27 Million	-257,269 Reduced 63.17%	150,000 $576,000
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $142,988 - $198,298	-31,426 Reduced 7.16%	407,269 $2.02 Million
Q3 2022 Oct 28, 2022	BUY	$4.48 - $6.47 $99,527 - $143,737	22,216 Added 5.33%	438,695 $2.1 Million
Q2 2022 Jul 25, 2022	SELL	$3.15 - $5.76 $719,841 - $1.32 Million	-228,521 Reduced 35.43%	416,479 $1.87 Million
Q1 2022 May 13, 2022	SELL	$4.26 - $7.48 $3.7 Million - $6.5 Million	-869,411 Reduced 57.41%	645,000 $3.07 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $4.11 Million - $6.48 Million	864,492 Added 133.02%	1,514,411 $11.2 Million
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $891,893 - $1.17 Million	-177,668 Reduced 21.47%	649,919 $3.69 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $568,711 - $844,717	98,223 Added 13.47%	827,587 $5.45 Million
Q1 2021 May 18, 2021	BUY	$6.5 - $10.53 $840,866 - $1.36 Million	129,364 Added 21.56%	729,364 $5.91 Million
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $2.22 Million - $4.6 Million	600,000 New	600,000 $3.87 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.